MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejps.2021.105788

Медицинская библиотека · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2021

Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice.

Liu Yihai, Wu Mingyue, Xu Jiamin, Xu Biao, Kang Lina

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been confirmed to reduce the rate of rehospitalization for heart failure and cardiovascular death in diabetic patients. The aim of our study was to investigate the cardioprotective role of SGLT2 inhibitors in early myocardial infarction (MI) of non-diabetic mice.

METHODS

C57BL/6 mice underwent left artery coronary artery descending (LAD) ligation to induce MI. Following the surgery, animals were randomized to receive saline or empagliflozin. Empagliflozin (EMPA) was administrated at 10 mg/kg per day by oral gavage for 2 weeks. Echocardiography, histological staining and qualitative RT-PCR were performed to assess the cardiac remodeling post MI. In vitro experiments were performed to evaluate the effect of empagliflozin on apoptosis, oxidative stress and mitochondrial membrane potential of cardiomyocyte subjected to hypoxic treatment.

RESULTS

Compared with MI group, the empagliflozin treatment group showed improved cardiac function, reduced infarct size and interstitial fibrosis. Empagliflozin also inhibited cardiomyocyte apoptosis by alleviating oxidative stress and restoring mitochondrial membrane potential. Immunoblotting analysis revealed activated AMP-activated protein kinase (AMPK) signaling may mediated the cardioprotective role of empagliflozin.

CONCLUSIONS

In summary, empagliflozin could inhibit cardiomyocyte apoptosis and improve cardiac remodeling early MI, which provided insights into the benefic effect of empagliflozin on MI patients without diabetes.

Для цитирования: Liu Yihai, Wu Mingyue, Xu Jiamin, Xu Biao, Kang Lina. Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice.. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2021. DOI: 10.1016/j.ejps.2021.105788.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.